Elutia Inc. (ELUT) 10-Year Financial Performance & Capital Metrics

ELUT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutElutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Show more

Revenue $24M -1.5%
EBITDA -$32M -19.2%
Net Income -$54M -43.3%
EPS (Diluted) -1.86 +10.1%
Gross Margin 43.93% -1.7%
EBITDA Margin -132.1% -21.0%
Operating Margin -146.26% -18.6%
Net Margin -221.33% -45.4%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.46 -41.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 10.7% over 5 years
✗Shares diluted 60.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.69%

3Y-19.88%

TTM-14.92%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM51.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.94%

ROCE

10Y Avg-77.61%

5Y Avg-103.54%

3Y Avg-166.9%

Latest-

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.04M	42.9M	42.68M	47.39M	23.85M	24.75M	24.38M
Revenue Growth %	-	0.1%	-0.01%	0.11%	-0.5%	0.04%	-0.01%
Cost of Goods Sold+	23.09M	23.13M	22.12M	28.37M	12.21M	13.69M	13.67M
COGS % of Revenue	0.59%	0.54%	0.52%	0.6%	0.51%	0.55%	0.56%
Gross Profit+	15.95M	19.77M	20.56M	19.02M	11.64M	11.05M	10.71M
Gross Margin %	0.41%	0.46%	0.48%	0.4%	0.49%	0.45%	0.44%
Gross Profit Growth %	-	0.24%	0.04%	-0.07%	-0.39%	-0.05%	-0.03%
Operating Expenses+	24.17M	28.18M	34.16M	42.05M	46.83M	41.58M	46.36M
OpEx % of Revenue	0.62%	0.66%	0.8%	0.89%	1.96%	1.68%	1.9%
Selling, General & Admin	21.68M	25.78M	28.21M	32.51M	33.9M	27.19M	31.2M
SG&A % of Revenue	0.56%	0.6%	0.66%	0.69%	1.42%	1.1%	1.28%
Research & Development	2.48M	2.4M	5.95M	9.27M	7.73M	4.4M	3.79M
R&D % of Revenue	0.06%	0.06%	0.14%	0.2%	0.32%	0.18%	0.16%
Other Operating Expenses	0	0	0	276K	5.2M	9.99M	11.37M
Operating Income+	-8.22M	-8.41M	-13.6M	-23.03M	-35.19M	-30.53M	-35.65M
Operating Margin %	-0.21%	-0.2%	-0.32%	-0.49%	-1.48%	-1.23%	-1.46%
Operating Income Growth %	-	-0.02%	-0.62%	-0.69%	-0.53%	0.13%	-0.17%
EBITDA+	-4.42M	-4.55M	-9.73M	-19.3M	-31.46M	-27.02M	-32.2M
EBITDA Margin %	-0.11%	-0.11%	-0.23%	-0.41%	-1.32%	-1.09%	-1.32%
EBITDA Growth %	-	-0.03%	-1.14%	-0.98%	-0.63%	0.14%	-0.19%
D&A (Non-Cash Add-back)	3.8M	3.86M	3.86M	3.73M	3.73M	3.51M	3.45M
EBIT	-6.02M	-6.53M	-16.17M	-19.45M	-31.03M	-35.42M	-49.34M
Net Interest Income+	-5.52M	-5.38M	-5.63M	-5.32M	-5.12M	-5.8M	-4.78M
Interest Income	0	0	0	0	0	0	0
Interest Expense	5.52M	5.38M	5.63M	5.32M	5.12M	5.8M	4.78M
Other Income/Expense	-3.32M	-3.5M	-8.2M	-1.75M	-959K	-10.7M	-18.47M
Pretax Income+	-11.54M	-11.91M	-21.8M	-24.78M	-36.15M	-41.22M	-54.12M
Pretax Margin %	-0.3%	-0.28%	-0.51%	-0.52%	-1.52%	-1.67%	-2.22%
Income Tax+	26K	30K	26K	55K	34K	28K	7K
Effective Tax Rate %	1%	1%	1%	1%	0.91%	0.91%	1%
Net Income+	-11.57M	-11.94M	-21.82M	-24.83M	-32.9M	-37.66M	-53.95M
Net Margin %	-0.3%	-0.28%	-0.51%	-0.52%	-1.38%	-1.52%	-2.21%
Net Income Growth %	-	-0.03%	-0.83%	-0.14%	-0.32%	-0.14%	-0.43%
Net Income (Continuing)	-11.57M	-11.94M	-21.82M	-24.83M	-36.18M	-41.25M	-54.13M
Discontinued Operations	0	0	0	0	3.29M	3.59M	180K
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-1.08	-1.12	-2.13	-2.38	-2.38	-2.07	-1.86
EPS Growth %	-	-0.04%	-0.9%	-0.12%	0%	0.13%	0.1%
EPS (Basic)	-1.08	-1.12	-2.13	-2.38	-2.38	-2.07	-1.86
Diluted Shares Outstanding	10.67M	10.67M	10.23M	10.44M	13.83M	18.16M	29.07M
Basic Shares Outstanding	10.67M	10.67M	10.23M	10.44M	13.83M	18.16M	29.07M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	18.14M	18.45M	59.71M	47.43M	50.7M	31.25M	26.17M
Cash & Short-Term Investments	2.41M	2.48M	39.15M	30.39M	16.99M	19.28M	13.24M
Cash Only	2.41M	2.48M	39.15M	30.39M	16.99M	19.28M	13.24M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	7.2M	7.23M	7.17M	6M	17.59M	5.96M	7.04M
Days Sales Outstanding	67.32	61.5	61.28	46.18	269.16	87.9	105.36
Inventory	7.46M	7.19M	10.12M	9.55M	4.24M	3.85M	3.91M
Days Inventory Outstanding	117.89	113.45	166.93	122.93	126.75	102.71	104.44
Other Current Assets	46K	108K	382K	35K	11.88M	2.17M	1.99M
Total Non-Current Assets+	29.61M	26.33M	23.1M	19.74M	18.14M	12.18M	9.96M
Property, Plant & Equipment	870K	988K	1.16M	1.2M	565K	504K	1.68M
Fixed Asset Turnover	44.87x	43.42x	36.73x	39.49x	42.21x	49.10x	14.49x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	25.26M	21.86M	18.47M	15.07M	11.67M	8.27M
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	28.74M	76K	76K	76K	2.51M	0	0
Total Assets+	47.74M	44.77M	82.81M	67.17M	68.84M	43.43M	36.13M
Asset Turnover	0.82x	0.96x	0.52x	0.71x	0.35x	0.57x	0.67x
Asset Growth %	-	-0.06%	0.85%	-0.19%	0.02%	-0.37%	-0.17%
Total Current Liabilities+	13.35M	18.27M	26.78M	26M	42.62M	43.04M	37.8M
Accounts Payable	1.59M	2.49M	2.05M	1.58M	1.37M	3.19M	4.15M
Days Payables Outstanding	25.12	39.32	33.89	20.36	41.07	85.07	110.8
Short-Term Debt	6.46M	5.92M	12.82M	12.82M	0	3.32M	1.71M
Deferred Revenue (Current)	0	650K	533K	5K	0	0	0
Other Current Liabilities	-1.26M	2.75M	2.75M	2.75M	31.28M	26.77M	24.83M
Current Ratio	1.36x	1.01x	2.23x	1.82x	1.19x	0.73x	0.69x
Quick Ratio	0.80x	0.62x	1.85x	1.46x	1.09x	0.64x	0.59x
Cash Conversion Cycle	160.1	135.63	194.32	148.75	354.84	105.55	99
Total Non-Current Liabilities+	77.8M	81.61M	35.2M	27.65M	31.26M	38.99M	44.59M
Long-Term Debt	75.92M	19.61M	17.81M	10.41M	24.26M	20.36M	22.6M
Capital Lease Obligations	0	0	0	0	956K	0	423K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.88M	61.29M	16.63M	16.54M	6.04M	18.64M	21.57M
Total Liabilities	91.15M	99.88M	61.98M	53.65M	73.87M	82.03M	82.39M
Total Debt+	82.39M	25.53M	30.64M	23.24M	25.45M	23.95M	24.74M
Net Debt	79.97M	23.05M	-8.52M	-7.16M	8.46M	4.68M	11.5M
Debt / Equity	-	-	1.47x	1.72x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-1.49x	-1.56x	-2.41x	-4.33x	-6.88x	-5.27x	-7.46x
Total Equity+	-43.41M	-55.11M	20.83M	13.52M	-5.03M	-38.6M	-46.26M
Equity Growth %	-	-0.27%	1.38%	-0.35%	-1.37%	-6.67%	-0.2%
Book Value per Share	-4.07	-5.17	2.04	1.29	-0.36	-2.13	-1.59
Total Shareholders' Equity	-43.41M	-55.11M	20.83M	13.52M	-5.03M	-38.6M	-46.26M
Common Stock	9K	1K	10K	13K	16K	23K	35K
Retained Earnings	-45M	-56.94M	-80.26M	-105.09M	-137.99M	-175.64M	-229.59M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	-56.94M	-80.26M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.13M	-7.22M	-13.63M	-15.45M	-21.43M	-21.76M	-22.66M
Operating CF Margin %	-0.13%	-0.17%	-0.32%	-0.33%	-0.9%	-0.88%	-0.93%
Operating CF Growth %	-	-0.41%	-0.89%	-0.13%	-0.39%	-0.02%	-0.04%
Net Income	-11.57M	-11.94M	-21.82M	-24.83M	-32.9M	-37.66M	-53.95M
Depreciation & Amortization	3.8M	3.86M	3.86M	3.73M	3.73M	3.73M	3.67M
Stock-Based Compensation	0	208K	779K	3.54M	3.65M	2.44M	7.89M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	9.02M	1.12M	6.22M	-254K	-1.63M	661K	15.64M
Working Capital Changes	1.38M	-467K	-2.67M	2.38M	5.71M	9.07M	4.09M
Change in Receivables	-1.61M	-30K	64K	1.17M	-14.65M	802K	527K
Change in Inventory	1.1M	269K	-2.93M	563K	-498K	-609K	-58K
Change in Payables	352K	-627K	0	0	0	0	0
Cash from Investing+	-190K	-577K	-640K	-369K	-540K	14.21M	-474K
Capital Expenditures	-190K	-577K	-640K	-369K	-540K	-346K	-654K
CapEx % of Revenue	0%	0.01%	0.01%	0.01%	0.02%	0.01%	0.03%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	14.55M	180K
Cash from Financing+	6.99M	7.98M	51.21M	6.71M	8.54M	9.84M	17.09M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	10.51M	-1.03M	-2.24M	-2.51M	-3.18M	11.83M	20.28M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-5.32M	-7.8M	-14.27M	-15.81M	-21.97M	-22.11M	-23.31M
FCF Margin %	-0.14%	-0.18%	-0.33%	-0.33%	-0.92%	-0.89%	-0.96%
FCF Growth %	-	-0.47%	-0.83%	-0.11%	-0.39%	-0.01%	-0.05%
FCF per Share	-0.50	-0.73	-1.40	-1.51	-1.59	-1.22	-0.80
FCF Conversion (FCF/Net Income)	0.44x	0.61x	0.62x	0.62x	0.65x	0.58x	0.42x
Interest Paid	3.47M	4.4M	5.11M	4.98M	5.48M	2.32M	12.69M
Taxes Paid	16K	25K	32K	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-104.77%	-144.57%	-775.14%	-	-
Return on Invested Capital (ROIC)	-16.86%	-280.05%	-82.81%	-184.94%	-539.1%	-	-
Gross Margin	40.84%	46.08%	48.17%	40.14%	48.8%	44.67%	43.93%
Net Margin	-29.63%	-27.83%	-51.13%	-52.4%	-137.94%	-152.18%	-221.33%
Debt / Equity	-	-	1.47x	1.72x	-	-	-
Interest Coverage	-1.49x	-1.56x	-2.41x	-4.33x	-6.88x	-5.27x	-7.46x
FCF Conversion	0.44x	0.61x	0.62x	0.62x	0.65x	0.58x	0.42x
Revenue Growth	-	9.9%	-0.51%	11.03%	-49.68%	3.76%	-1.5%

Revenue by Segment

	2023	2024
Women's Health	10.3M	11.55M
Women's Health Growth	-	12.12%
Cardiovascular	5.04M	2.92M
Cardiovascular Growth	-	-42.16%

Frequently Asked Questions

Growth & Financials

Elutia Inc. (ELUT) reported $21.1M in revenue for fiscal year 2024. This represents a 46% decrease from $39.0M in 2018.

Elutia Inc. (ELUT) saw revenue decline by 1.5% over the past year.

Elutia Inc. (ELUT) reported a net loss of $26.5M for fiscal year 2024.

Dividend & Returns

Elutia Inc. (ELUT) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Elutia Inc. (ELUT) 10-Year Financial Performance & Capital Metrics

ELUT • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $24M -1.5%
EBITDA -$32M -19.2%
Net Income -$54M -43.3%
EPS (Diluted) -1.86 +10.1%
Gross Margin 43.93% -1.7%
EBITDA Margin -132.1% -21.0%
Operating Margin -146.26% -18.6%
Net Margin -221.33% -45.4%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -7.46 -41.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 10.7% over 5 years
✗Shares diluted 60.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.69%

3Y-19.88%

TTM-14.92%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM51.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.94%

ROCE

10Y Avg-77.61%

5Y Avg-103.54%

3Y Avg-166.9%

Latest-

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.04M	42.9M	42.68M	47.39M	23.85M	24.75M	24.38M
Revenue Growth %	-	0.1%	-0.01%	0.11%	-0.5%	0.04%	-0.01%
Cost of Goods Sold+	23.09M	23.13M	22.12M	28.37M	12.21M	13.69M	13.67M
COGS % of Revenue	0.59%	0.54%	0.52%	0.6%	0.51%	0.55%	0.56%
Gross Profit+	15.95M	19.77M	20.56M	19.02M	11.64M	11.05M	10.71M
Gross Margin %	0.41%	0.46%	0.48%	0.4%	0.49%	0.45%	0.44%
Gross Profit Growth %	-	0.24%	0.04%	-0.07%	-0.39%	-0.05%	-0.03%
Operating Expenses+	24.17M	28.18M	34.16M	42.05M	46.83M	41.58M	46.36M
OpEx % of Revenue	0.62%	0.66%	0.8%	0.89%	1.96%	1.68%	1.9%
Selling, General & Admin	21.68M	25.78M	28.21M	32.51M	33.9M	27.19M	31.2M
SG&A % of Revenue	0.56%	0.6%	0.66%	0.69%	1.42%	1.1%	1.28%
Research & Development	2.48M	2.4M	5.95M	9.27M	7.73M	4.4M	3.79M
R&D % of Revenue	0.06%	0.06%	0.14%	0.2%	0.32%	0.18%	0.16%
Other Operating Expenses	0	0	0	276K	5.2M	9.99M	11.37M
Operating Income+	-8.22M	-8.41M	-13.6M	-23.03M	-35.19M	-30.53M	-35.65M
Operating Margin %	-0.21%	-0.2%	-0.32%	-0.49%	-1.48%	-1.23%	-1.46%
Operating Income Growth %	-	-0.02%	-0.62%	-0.69%	-0.53%	0.13%	-0.17%
EBITDA+	-4.42M	-4.55M	-9.73M	-19.3M	-31.46M	-27.02M	-32.2M
EBITDA Margin %	-0.11%	-0.11%	-0.23%	-0.41%	-1.32%	-1.09%	-1.32%
EBITDA Growth %	-	-0.03%	-1.14%	-0.98%	-0.63%	0.14%	-0.19%
D&A (Non-Cash Add-back)	3.8M	3.86M	3.86M	3.73M	3.73M	3.51M	3.45M
EBIT	-6.02M	-6.53M	-16.17M	-19.45M	-31.03M	-35.42M	-49.34M
Net Interest Income+	-5.52M	-5.38M	-5.63M	-5.32M	-5.12M	-5.8M	-4.78M
Interest Income	0	0	0	0	0	0	0
Interest Expense	5.52M	5.38M	5.63M	5.32M	5.12M	5.8M	4.78M
Other Income/Expense	-3.32M	-3.5M	-8.2M	-1.75M	-959K	-10.7M	-18.47M
Pretax Income+	-11.54M	-11.91M	-21.8M	-24.78M	-36.15M	-41.22M	-54.12M
Pretax Margin %	-0.3%	-0.28%	-0.51%	-0.52%	-1.52%	-1.67%	-2.22%
Income Tax+	26K	30K	26K	55K	34K	28K	7K
Effective Tax Rate %	1%	1%	1%	1%	0.91%	0.91%	1%
Net Income+	-11.57M	-11.94M	-21.82M	-24.83M	-32.9M	-37.66M	-53.95M
Net Margin %	-0.3%	-0.28%	-0.51%	-0.52%	-1.38%	-1.52%	-2.21%
Net Income Growth %	-	-0.03%	-0.83%	-0.14%	-0.32%	-0.14%	-0.43%
Net Income (Continuing)	-11.57M	-11.94M	-21.82M	-24.83M	-36.18M	-41.25M	-54.13M
Discontinued Operations	0	0	0	0	3.29M	3.59M	180K
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-1.08	-1.12	-2.13	-2.38	-2.38	-2.07	-1.86
EPS Growth %	-	-0.04%	-0.9%	-0.12%	0%	0.13%	0.1%
EPS (Basic)	-1.08	-1.12	-2.13	-2.38	-2.38	-2.07	-1.86
Diluted Shares Outstanding	10.67M	10.67M	10.23M	10.44M	13.83M	18.16M	29.07M
Basic Shares Outstanding	10.67M	10.67M	10.23M	10.44M	13.83M	18.16M	29.07M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	18.14M	18.45M	59.71M	47.43M	50.7M	31.25M	26.17M
Cash & Short-Term Investments	2.41M	2.48M	39.15M	30.39M	16.99M	19.28M	13.24M
Cash Only	2.41M	2.48M	39.15M	30.39M	16.99M	19.28M	13.24M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	7.2M	7.23M	7.17M	6M	17.59M	5.96M	7.04M
Days Sales Outstanding	67.32	61.5	61.28	46.18	269.16	87.9	105.36
Inventory	7.46M	7.19M	10.12M	9.55M	4.24M	3.85M	3.91M
Days Inventory Outstanding	117.89	113.45	166.93	122.93	126.75	102.71	104.44
Other Current Assets	46K	108K	382K	35K	11.88M	2.17M	1.99M
Total Non-Current Assets+	29.61M	26.33M	23.1M	19.74M	18.14M	12.18M	9.96M
Property, Plant & Equipment	870K	988K	1.16M	1.2M	565K	504K	1.68M
Fixed Asset Turnover	44.87x	43.42x	36.73x	39.49x	42.21x	49.10x	14.49x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	25.26M	21.86M	18.47M	15.07M	11.67M	8.27M
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	28.74M	76K	76K	76K	2.51M	0	0
Total Assets+	47.74M	44.77M	82.81M	67.17M	68.84M	43.43M	36.13M
Asset Turnover	0.82x	0.96x	0.52x	0.71x	0.35x	0.57x	0.67x
Asset Growth %	-	-0.06%	0.85%	-0.19%	0.02%	-0.37%	-0.17%
Total Current Liabilities+	13.35M	18.27M	26.78M	26M	42.62M	43.04M	37.8M
Accounts Payable	1.59M	2.49M	2.05M	1.58M	1.37M	3.19M	4.15M
Days Payables Outstanding	25.12	39.32	33.89	20.36	41.07	85.07	110.8
Short-Term Debt	6.46M	5.92M	12.82M	12.82M	0	3.32M	1.71M
Deferred Revenue (Current)	0	650K	533K	5K	0	0	0
Other Current Liabilities	-1.26M	2.75M	2.75M	2.75M	31.28M	26.77M	24.83M
Current Ratio	1.36x	1.01x	2.23x	1.82x	1.19x	0.73x	0.69x
Quick Ratio	0.80x	0.62x	1.85x	1.46x	1.09x	0.64x	0.59x
Cash Conversion Cycle	160.1	135.63	194.32	148.75	354.84	105.55	99
Total Non-Current Liabilities+	77.8M	81.61M	35.2M	27.65M	31.26M	38.99M	44.59M
Long-Term Debt	75.92M	19.61M	17.81M	10.41M	24.26M	20.36M	22.6M
Capital Lease Obligations	0	0	0	0	956K	0	423K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.88M	61.29M	16.63M	16.54M	6.04M	18.64M	21.57M
Total Liabilities	91.15M	99.88M	61.98M	53.65M	73.87M	82.03M	82.39M
Total Debt+	82.39M	25.53M	30.64M	23.24M	25.45M	23.95M	24.74M
Net Debt	79.97M	23.05M	-8.52M	-7.16M	8.46M	4.68M	11.5M
Debt / Equity	-	-	1.47x	1.72x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-1.49x	-1.56x	-2.41x	-4.33x	-6.88x	-5.27x	-7.46x
Total Equity+	-43.41M	-55.11M	20.83M	13.52M	-5.03M	-38.6M	-46.26M
Equity Growth %	-	-0.27%	1.38%	-0.35%	-1.37%	-6.67%	-0.2%
Book Value per Share	-4.07	-5.17	2.04	1.29	-0.36	-2.13	-1.59
Total Shareholders' Equity	-43.41M	-55.11M	20.83M	13.52M	-5.03M	-38.6M	-46.26M
Common Stock	9K	1K	10K	13K	16K	23K	35K
Retained Earnings	-45M	-56.94M	-80.26M	-105.09M	-137.99M	-175.64M	-229.59M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	-56.94M	-80.26M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.13M	-7.22M	-13.63M	-15.45M	-21.43M	-21.76M	-22.66M
Operating CF Margin %	-0.13%	-0.17%	-0.32%	-0.33%	-0.9%	-0.88%	-0.93%
Operating CF Growth %	-	-0.41%	-0.89%	-0.13%	-0.39%	-0.02%	-0.04%
Net Income	-11.57M	-11.94M	-21.82M	-24.83M	-32.9M	-37.66M	-53.95M
Depreciation & Amortization	3.8M	3.86M	3.86M	3.73M	3.73M	3.73M	3.67M
Stock-Based Compensation	0	208K	779K	3.54M	3.65M	2.44M	7.89M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	9.02M	1.12M	6.22M	-254K	-1.63M	661K	15.64M
Working Capital Changes	1.38M	-467K	-2.67M	2.38M	5.71M	9.07M	4.09M
Change in Receivables	-1.61M	-30K	64K	1.17M	-14.65M	802K	527K
Change in Inventory	1.1M	269K	-2.93M	563K	-498K	-609K	-58K
Change in Payables	352K	-627K	0	0	0	0	0
Cash from Investing+	-190K	-577K	-640K	-369K	-540K	14.21M	-474K
Capital Expenditures	-190K	-577K	-640K	-369K	-540K	-346K	-654K
CapEx % of Revenue	0%	0.01%	0.01%	0.01%	0.02%	0.01%	0.03%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	14.55M	180K
Cash from Financing+	6.99M	7.98M	51.21M	6.71M	8.54M	9.84M	17.09M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	10.51M	-1.03M	-2.24M	-2.51M	-3.18M	11.83M	20.28M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-5.32M	-7.8M	-14.27M	-15.81M	-21.97M	-22.11M	-23.31M
FCF Margin %	-0.14%	-0.18%	-0.33%	-0.33%	-0.92%	-0.89%	-0.96%
FCF Growth %	-	-0.47%	-0.83%	-0.11%	-0.39%	-0.01%	-0.05%
FCF per Share	-0.50	-0.73	-1.40	-1.51	-1.59	-1.22	-0.80
FCF Conversion (FCF/Net Income)	0.44x	0.61x	0.62x	0.62x	0.65x	0.58x	0.42x
Interest Paid	3.47M	4.4M	5.11M	4.98M	5.48M	2.32M	12.69M
Taxes Paid	16K	25K	32K	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-104.77%	-144.57%	-775.14%	-	-
Return on Invested Capital (ROIC)	-16.86%	-280.05%	-82.81%	-184.94%	-539.1%	-	-
Gross Margin	40.84%	46.08%	48.17%	40.14%	48.8%	44.67%	43.93%
Net Margin	-29.63%	-27.83%	-51.13%	-52.4%	-137.94%	-152.18%	-221.33%
Debt / Equity	-	-	1.47x	1.72x	-	-	-
Interest Coverage	-1.49x	-1.56x	-2.41x	-4.33x	-6.88x	-5.27x	-7.46x
FCF Conversion	0.44x	0.61x	0.62x	0.62x	0.65x	0.58x	0.42x
Revenue Growth	-	9.9%	-0.51%	11.03%	-49.68%	3.76%	-1.5%

Revenue by Segment

	2023	2024
Women's Health	10.3M	11.55M
Women's Health Growth	-	12.12%
Cardiovascular	5.04M	2.92M
Cardiovascular Growth	-	-42.16%

Frequently Asked Questions

Growth & Financials

Elutia Inc. (ELUT) reported $21.1M in revenue for fiscal year 2024. This represents a 46% decrease from $39.0M in 2018.

Elutia Inc. (ELUT) saw revenue decline by 1.5% over the past year.

Elutia Inc. (ELUT) reported a net loss of $26.5M for fiscal year 2024.

Dividend & Returns

Elutia Inc. (ELUT) had negative free cash flow of $29.9M in fiscal year 2024, likely due to heavy capital investments.